FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2543965487> ?p ?o ?g. }

• W2543965487 endingPage "5967" @default.
• W2543965487 startingPage "5959" @default.
• W2543965487 abstract "Despite the availability of safe and effective human vaccines, rabies remains a global threat, with an estimated 60,000 human deaths annually attributed to rabies. Pre-exposure prophylaxis against rabies infection is recommended for travelers to countries where rabies is endemic, and also for those with a higher risk of exposure. In this study, the rabies-specific neutralising antibody responses in a cohort of rabies-vaccinated recipients over a period of twenty years have been assessed. In particular, the antibody response to primary vaccinations and boosters, and the waning of antibody post primary vaccination and post booster were investigated. The significance of gender, age at vaccination, vaccine manufacturer and vaccination intervals were also evaluated. These data confirm that rabies vaccination can elicit a neutralising antibody response that can remain at detectable levels for a number of years, without additional booster vaccinations. The antibody response following both primary vaccination and booster was significantly influenced by the gender of the subject (p=0.002 and 0.03 respectively), with supportive data that suggests an effect by the make of vaccine administered following primary vaccination, with significantly higher VNA titres observed for one vaccine manufactured prior to 2006 (p<0.001) in a small subset of recipients (n=5). Additionally, the decay rate was demonstrated through the overall decline in antibody titre for all individuals, which was a 37% and 27% reduction per 2-fold change in time following primary and booster vaccination respectively. Individuals within older age groups demonstrated a significantly faster decline in antibody titre following the primary vaccination course (p=0.012). Rate of decline in antibody titre was also significantly influenced by the vaccine make following primary course (p<0.001). The assessment of neutralising antibody titre decline has also provided an insight into the most appropriate timing for booster administration, and enabled the prediction of long term titres from post-vaccination antibody titres." @default.
• W2543965487 created "2016-11-04" @default.
• W2543965487 creator A5020456334 @default.
• W2543965487 creator A5027463016 @default.
• W2543965487 creator A5045511222 @default.
• W2543965487 creator A5056001873 @default.
• W2543965487 creator A5064630106 @default.
• W2543965487 creator A5072485453 @default.
• W2543965487 creator A5085033887 @default.
• W2543965487 date "2016-11-01" @default.
• W2543965487 modified "2023-09-26" @default.
• W2543965487 title "Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans" @default.
• W2543965487 cites W1964998554 @default.
• W2543965487 cites W1965536088 @default.
• W2543965487 cites W1970179868 @default.
• W2543965487 cites W1977773205 @default.
• W2543965487 cites W1987606929 @default.
• W2543965487 cites W1989888538 @default.
• W2543965487 cites W1996345364 @default.
• W2543965487 cites W2001564185 @default.
• W2543965487 cites W2004693124 @default.
• W2543965487 cites W2011108892 @default.
• W2543965487 cites W2016093815 @default.
• W2543965487 cites W2022119748 @default.
• W2543965487 cites W2027663660 @default.
• W2543965487 cites W2042187206 @default.
• W2543965487 cites W2045479849 @default.
• W2543965487 cites W2054775296 @default.
• W2543965487 cites W2056160735 @default.
• W2543965487 cites W2061286330 @default.
• W2543965487 cites W2065780425 @default.
• W2543965487 cites W2069401171 @default.
• W2543965487 cites W2072380958 @default.
• W2543965487 cites W2094690130 @default.
• W2543965487 cites W2105889293 @default.
• W2543965487 cites W2111937747 @default.
• W2543965487 cites W2113336711 @default.
• W2543965487 cites W2114256073 @default.
• W2543965487 cites W2115130178 @default.
• W2543965487 cites W2132658398 @default.
• W2543965487 cites W2207407445 @default.
• W2543965487 cites W2211764956 @default.
• W2543965487 cites W95708866 @default.
• W2543965487 doi "https://doi.org/10.1016/j.vaccine.2016.09.058" @default.
• W2543965487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27997343" @default.
• W2543965487 hasPublicationYear "2016" @default.
• W2543965487 type Work @default.
• W2543965487 sameAs 2543965487 @default.
• W2543965487 citedByCount "29" @default.
• W2543965487 countsByYear W25439654872018 @default.
• W2543965487 countsByYear W25439654872019 @default.
• W2543965487 countsByYear W25439654872020 @default.
• W2543965487 countsByYear W25439654872021 @default.
• W2543965487 countsByYear W25439654872022 @default.
• W2543965487 countsByYear W25439654872023 @default.
• W2543965487 crossrefType "journal-article" @default.
• W2543965487 hasAuthorship W2543965487A5020456334 @default.
• W2543965487 hasAuthorship W2543965487A5027463016 @default.
• W2543965487 hasAuthorship W2543965487A5045511222 @default.
• W2543965487 hasAuthorship W2543965487A5056001873 @default.
• W2543965487 hasAuthorship W2543965487A5064630106 @default.
• W2543965487 hasAuthorship W2543965487A5072485453 @default.
• W2543965487 hasAuthorship W2543965487A5085033887 @default.
• W2543965487 hasConcept C121332964 @default.
• W2543965487 hasConcept C12590561 @default.
• W2543965487 hasConcept C1276947 @default.
• W2543965487 hasConcept C159047783 @default.
• W2543965487 hasConcept C159654299 @default.
• W2543965487 hasConcept C203014093 @default.
• W2543965487 hasConcept C203165030 @default.
• W2543965487 hasConcept C22070199 @default.
• W2543965487 hasConcept C22889606 @default.
• W2543965487 hasConcept C2776849203 @default.
• W2543965487 hasConcept C2777961786 @default.
• W2543965487 hasConcept C2779341262 @default.
• W2543965487 hasConcept C2780674857 @default.
• W2543965487 hasConcept C32611913 @default.
• W2543965487 hasConcept C71924100 @default.
• W2543965487 hasConcept C8891405 @default.
• W2543965487 hasConceptScore W2543965487C121332964 @default.
• W2543965487 hasConceptScore W2543965487C12590561 @default.
• W2543965487 hasConceptScore W2543965487C1276947 @default.
• W2543965487 hasConceptScore W2543965487C159047783 @default.
• W2543965487 hasConceptScore W2543965487C159654299 @default.
• W2543965487 hasConceptScore W2543965487C203014093 @default.
• W2543965487 hasConceptScore W2543965487C203165030 @default.
• W2543965487 hasConceptScore W2543965487C22070199 @default.
• W2543965487 hasConceptScore W2543965487C22889606 @default.
• W2543965487 hasConceptScore W2543965487C2776849203 @default.
• W2543965487 hasConceptScore W2543965487C2777961786 @default.
• W2543965487 hasConceptScore W2543965487C2779341262 @default.
• W2543965487 hasConceptScore W2543965487C2780674857 @default.
• W2543965487 hasConceptScore W2543965487C32611913 @default.
• W2543965487 hasConceptScore W2543965487C71924100 @default.
• W2543965487 hasConceptScore W2543965487C8891405 @default.
• W2543965487 hasFunder F4320319995 @default.
• W2543965487 hasIssue "48" @default.
• W2543965487 hasLocation W25439654871 @default.

• next